David Simpson

76 papers receiving 2.2k citations

David Simpson's Hit Papers

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study 2019 · 320 citations
3200+4+8Years since publication100200300400

Peers

David Simpson
Comparison fields: 5 of 101
  • Genetics 1.1k
  • Pathology and Forensic Medicine 1.2k
  • Hematology 381
  • Oncology 718
  • Immunology 279
Replace R. Gregory Bociek with:
R. Gregory Bociek United States
Beatrice Mahé France
V. Leblond France
Mazyar Shadman United States
Charles W. Ross United States
Zale P. Bernstein United States
Daniel Li United States
Donna L. Forrest Canada
Patrizio Mazza Italy
J. M. A. Whitehouse United Kingdom
David Simpson relative to R. Gregory Bociek United States R. Gregory Bociek's profile →
Citations per field
00.5×1.5×2.2×
R. Gregory Bociek · 1×
Citations per year

Countries citing papers authored by David Simpson

Since Specialization
Citations

This map shows the geographic impact of David Simpson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Simpson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Simpson more than expected).

Fields of papers citing papers by David Simpson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Simpson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Simpson. The network helps show where David Simpson may publish in the future.

Co-authors

The 25 scholars most cited alongside David Simpson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Simpson Line = papers co-authored together David Simpson links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 77 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Hit paper breakdown →
2014430
2
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Hit paper breakdown →
2019320
3 2019179
4 2005122
5 202077
6 200973
7 201472
8 201869
9 202165
10 201962
11 201759
12 200249
13 200446
14 202133
15 201729
16 202129
17 201627
18 201226
19 201924
20 201824

About David Simpson

David Simpson is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Oncology and Pulmonary and Respiratory Medicine, having authored 77 papers that have together received 2.2k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (45 papers), Lymphoma Diagnosis and Treatment (35 papers), Chronic Myeloid Leukemia Treatments (14 papers), Multiple Myeloma Research and Treatments (8 papers), Cancer Treatment and Pharmacology (7 papers), Acute Lymphoblastic Leukemia research (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Viral-associated cancers and disorders (5 papers). The work is most often cited by research in Genetics (1.1k citations), Pathology and Forensic Medicine (1.2k citations), Hematology (381 citations), Oncology (718 citations) and Immunology (279 citations). David Simpson has collaborated with scholars based in New Zealand, United States and Australia. Frequent co-authors include Samar Issa, Peter Wood, Kathryn S. Kolibaba, David MacDonald, Ian W. Flinn, John M. Burke, Tim E. Hawkins, Brad S. Kahl, Doreen M. Hallman and Richard van der Jagt. Their work appears in journals such as Blood, Journal of Clinical Oncology, Hematological Oncology, HemaSphere and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact